Clay Siegall posts depict a person who is driven by the ambition of informing the society and exploring his hobby. Based on his blog posts, it is evident that he is an individual who has interest in sports. In one of his posts, he informs the readers the on the reason behind Buccaneers- Dolphins move to week 11. Based on his post, he states that this was due to the threat of climatic challenge posed by the Hurricane Irma.
In another post, Clay Siegall readings explore predictions of 256 games of the season. Although he is a CEO of a biotechnology firm, his posts show that he is a person who is well acquainted with the happenings in the world. In such a post exploring game predictions, it is evident that he takes some time on his hobby. Moreover, his posts inform readers on new happenings in the sports domain.
Dr. Clay Siegall is a co- founder of a biotechnology organization named Seattle Genetics. The company was founded in 1998. Dr. Clay currently serves as the president of the company, chairman of the board of directors and as the chief executive officer of the organization. Under the leadership of Dr. Clay, the company has been able to build various antibody based cancer therapies. As such, it is a significant organization in the fight against cancer.
One of the therapies that were given accelerated approval by FDA in 2011 is the ADCETRIS. Some of the roles that he has played include engaging in the Seattle Genetics capital raising activities which led to the securing of more than $675 million in both the private and public funding. Before being a co-founder of Seattle Genetics, Dr. Clay Siegall worked with Bristol Myers Squibb Pharmaceutical Research Institute. He also worked with the National Cancer Institute. By working in such organizations, he is experienced in pioneering the needed change towards combating cancer.
In addition to being an influential person to Seattle Genetics, he serves as a member of the board of directors in a private biotechnology company named Alder Biopharmaceuticals. He is an author of more than seventy publications and an owner of fifteen patents.